Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Andrew McGarry, Shane Rosanbalm, Mika Leinonen, C. Warren Olanow, Dennis To, Adam Bell, Daniel Lee, Jamie Chang, Jordan Dubow, Rohit Dhall, Daniel Burdick, Sotirios Parashos, Jeanne Feuerstein, Joseph Quinn, Rajesh Pahwa, Mitra Afshari, Aldolfo Ramirez-Zamora, Kelvin Chou, Arjun Tarakad, Corneliu LucaKevin Klos, Yvette Bordelon, Marie Helene St Hiliare, David Shprecher, Seulki Lee, Ted M. Dawson, Viktor Roschke, Karl Kieburtz
Dive into the research topics of 'Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.